Surging Trumid RFQ activity and record Investment Grade market share drive 19% YoY ADV growth Trumid, a financial technology company and leading fixed income electronic trading platform, today announced trade volume and user participation highlights for October 2025. https://mma.prnewswire.com/media/2544830/Trumid_Logo.jpg List trading protocols continued to drive growth, with combined Trumid RFQ and Portfolio Trading ADV up […]
Celldex to Present at Upcoming Investor Conferences GlobeNewswire November 07, 2025 HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) — Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11 at 10:00 am ET TD Cowen Immunology & Inflammation
(CNSX:MAXX),(CNSX:MAXX.CN),(Pinksheets:MAXXF),(PinkSheets:MAXXF),(Boerse Frankfurt – Freiverkehr:89N.F),(Boerse Frankfurt – Freiverkehr:89N), The Lawson Target Exhibits All Five Key Elements for a Potential Natural Hydrogen Accumulation Including Source Rocks, Migration Pathways, Reservoirs, Seals and Traps, Along With a Defined Four-Way Structural Closure MAX Power Saskatchewan Natural Hydrogen Documentary Videohttps://www.maxpowermining.com/NaturalHydrogen-NewEra/ SASKATOON, Saskatchewan, Nov. 07, 2025 (GLOBE NEWSWIRE) — MAX Power Mining
Braemar Hotels & Resorts Inc. (NYSE: BHR) (“Braemar” or the “Company”) announced today that it has closed on the previously announced sale of the 410-room The Clancy in San Francisco for $115 million ($280,487 per key). The sale price represents a 5.2% capitalization rate on net operating income for the trailing 12 months ended September
(NASDAQ:REGN), Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years and older compared to placebo Dupixent sBLA accepted for priority review by the U.S. FDA with a target action date of February 28, 2026
Ultra-Wideband (UWB) is rapidly becoming a foundational wireless connectivity technology, offering unique benefits compared with other short-range wireless solutions such as Wi-Fi, Bluetooth®, IEEE 802.15.4, and Near Field Communication (NFC). The combination of secure ranging, radar, and sensing capabilities, along with its potential to serve as a low-latency, high-throughput communications technology over short distances, is
(NASDAQ:BFRI),(NASDAQ:BFRIW), Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash position, which is expected to fund Biofrontera to profitability. Proceeds will support the growth of Biofrontera's commercial photodynamic therapy (PDT) platform,
(Madrid:ORY.MC),(Boerse Stuttgart – Freiverkehr:ORN),(Madrid:ORY),(Boerse Stuttgart – Freiverkehr:ORN.SG), The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green CNS (Vafidemstat) Received feedback from the FDA on Phase III PORTICO-2 trial in BPD; Company to revise protocol and resubmit Reinforcing company's clinical,
(NASDAQ:VXRT),(OTC US:VXRT),(Other OTC:VXRT), Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”) today announced it will host two upcoming webcast
(NYSE MKT:PTHS), Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI(TM) Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting children Impetigo affects approximately 3 million people in the U.S. every year and